GSK plc 6-K, filed Feb 22, 2022
GSK plc (GSK)
6-K
2022-02-22
For: 2022-02-22
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on February 22, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 22 February 2022, London UK
GSK announces independent Consumer Healthcare company is to be
called Haleon
●
Haleon will be a new world-leader in consumer
health with an exceptional portfolio of category-leading brands,
including Sensodyne, Voltaren, Panadol and Centrum
●
Business
is on track to demerge and list as a new company in
mid-2022
GlaxoSmithKline plc (GSK) today announced that the new company, to
result from the proposed demerger of Consumer Healthcare from GSK
in mid-2022, will be called Haleon.
Haleon (pronounced "Hay-Lee-On") is inspired by the merging of the
words 'Hale', which is an old English word that means 'in good
health' and Leon, which is associated with the word
'strength'. The new brand
identity was developed with input from employees, healthcare
practitioners and consumers and will be deployed in more than 100
markets around the world where the business
operates.
The creation of Haleon results from a series of successful
investments and strategic changes to GSK's consumer health business
over the last 8 years, including integrations of the consumer
product portfolios from Novartis and Pfizer. It is now a highly
valuable and focused global business generating annual sales of
approximately £10 billion[1].
As a standalone company, Haleon will be a new world-leader in
consumer healthcare, offering a compelling proposition - to bring
deep human understanding together with trusted science - to deliver
better everyday health with humanity.
Brian McNamara, Chief Executive Officer Designate,
Haleon, said:
"Introducing Haleon to the world marks another step in our journey
to become a new, standalone company. Our name is grounded in our
purpose to deliver better everyday health with humanity and to
be a world-leader in consumer healthcare. We are on track to launch
Haleon in mid-2022 and our business momentum is strong. We look
forward to updating investors and analysts more on this at our
capital markets event at the end of February."
Emma Walmsley, Chief Executive Officer, GSK,
said: "Haleon brings to
life years of hard work by many outstanding people to build this
new company purely dedicated to everyday health. Haleon has
enormous potential to improve health and wellbeing across the world
with strong prospects for growth, and through listing will unlock
significant value for GSK shareholders."
Haleon will have a world-class portfolio of category-leading
global brands, including Sensodyne, Voltaren,
Panadol and Centrum. Its brands are trusted by healthcare
professionals, customers and people worldwide to improve the health
and wellbeing of individuals and their communities. Demand from the
£150 billion consumer healthcare sector is strong, reflecting
an increased focus on health and wellness, significant demand from
an ageing population and emerging middle-class, and unmet consumer
needs. The business is therefore well-positioned to deliver human
health impact and to sustainably grow ahead of the market in the
years to come.
The new name was announced as part of a global celebration for all
of the people working in GSK Consumer Healthcare earlier
today. Employees from around the world had the opportunity to
engage with the new name and brand identity which seeks to
bring to life the company's purpose and growth
ambitions.
The name was also announced in advance of GSK hosting a Consumer
Healthcare Capital Markets Day for investors and analysts on Monday
28 February, to provide details on the overall strategy,
capabilities and operations of Haleon, including detailed financial
information and growth ambitions of the business. For prospective
investors, Haleon will offer attractive organic sales growth,
operating margin expansion and consistent high cash
generation.
Notes to editors
●
As
set out at GSK's Investor Update in June 2021, subject to approval
from shareholders, the separation of Consumer Healthcare will be by
way of a demerger in mid-2022 of at least 80% of GSK's holding to
shareholders.
●
Haleon
will be headquartered in Weybridge, UK, and is expected to attain a
premium listing on the London Stock Exchange, with ADRs to be
listed in the US.
●
The
new Weybridge campus is expected to open at the end of 2024 and,
alongside being the new company's corporate headquarters, will be a
centre of R&D and innovation, and home to a new
state-of-the-art Shopper Science Lab.
●
In
July 2021, the Board of GSK confirmed Brian McNamara as CEO
Designate and in December 2021, announced the appointment of Sir
Dave Lewis as Chair Designate of the new company to result from the
proposed demerger of Consumer Healthcare from
GSK.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Madeleine
Breckon
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Evan
Berland
|
+1 215 432 0234
|
(Philadelphia)
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
Emma
White
|
+44 (0)
7823 523562
|
(Consumer)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020, GSK's 2021 Q4 Results and any
impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[1] Sales
in FY2021 £9.6 billion, including Brands divested/under
review; £9.5bn continuing sales
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
22, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|